Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

H.C. Wainwright lowered the firm’s price target on Annexon (ANNX) to $20 from $30 and keeps a Buy rating on the shares. The positive SAD/MAD ...

Commit is developing its Bispecific Complement Engaging (BiCE) platform, which uses single domain antibodies that bind to the complement protein C1q to activate and direct the complement system ...